中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月8日星期二
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (24): 92-94-98    
  检验医学 本期目录 | 过刊浏览 | 高级检索 |
D-二聚体、NLR、BNP联合检测在慢性阻塞性肺疾病急性加重期诊治中的临床应用价值
肖士滨1 张裕芳2 黄昌艳1
1.江西省赣州市立医院检验科,江西赣州 341000;
2.江西省赣州市立医院输血科,江西赣州 341000
Clinical application value of combined detection of D-dimer, NLR and BNP in the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary diseas
XIAO Shibin1 ZHANG Yufang2 HUANG Changyan1
1. Department of Laboratory, Ganzhou Municipal Hospital, Jiangxi Province, Ganzhou 341000, China; 
2. Department of Blood Transfusion, Ganzhou Municipal Hospital, Jiangxi Province, Ganzhou 341000, China
全文: PDF (461 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探究D-二聚体(D-D)、中性粒细胞/淋巴细胞比值(NLR)、B 型脑钠肽(BNP)联合检测在慢性阻塞性肺疾病急性加重期(AECOPD)诊治中的临床应用价值。 方法 选取2021年1月至2021年12月赣州市立医院收治的160 例慢性阻塞性肺疾病(COPD)患者作为研究对象,根据病情将急性加重期患者设为观察组,将稳定期患者设为对照组。 对两组患者的D-D、NLR、BNP 水平进行检测并比较,采用Pearson 相关性分析统计D-D、NLR 与BNP 的相关性,并通过受试者工作特征曲线(ROC)分析D-D、NLR 与BNP 对AECOPD 诊断价值。 结果 观察组患者BNP 水平低于对照组,D-D、NLR 水平高于对照组,差异有统计学意义(P<0.05)。 相关性分析显示,D-D、NLR与BNP 均呈显著负相关(r=-0.803、-0.862,P<0.001)。ROC 分析结果显示D-D、NLR、BNP 与联合诊断肝硬化的截断值分别为1.525、5.740、200.075、0.485,曲线下面积分别为0.974、0.993、1.000、1.000,联合诊断曲线下面积高于单独诊断。结论D-D、NLR、BNP 联合检测在AECOPD 的诊治中具有较高的灵敏度和特异度,诊断价值高,值得临床推广。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
肖士滨
张裕芳
黄昌艳
关键词 慢性阻塞性肺疾病急性加重期D-二聚体中性粒细胞/淋巴细胞比值B 型脑钠肽诊断价值    
Abstract:Objective To investigate the clinical application value of the combined detection of D-dimer (D-D),neutrophilto lymphocyte ratio (NLR) and B-type natriuretic peptide (BNP) in the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 160 patients with chronic obstructive pulmonary disease (COPD) in Ganzhou Municipal Hospital from January 2021 to December 2021 were selected as the research objects. According to the conditions, the patients in the acute exacerbation stage were set as the observation group, and the patients in the stable stage were set as the control group. The levels of D-D, NLR and BNP in the two groups were detected and compared, and the Pearson correlation was used to analyze the correlation among D-D, NLR and BNP, and the receiver operating characteristic curve (ROC) was used to analyze the diagnosis of AECOPD by D-D, NLR and BNP value. Results The levels of BNP in the observation group were lower than those in the control group, and the levels of D-D and NLR were higher than those in the control group, the differences were statistically significant (P<0.05). The correlation analysis showed that D-D, NLR and BNP were all negatively correlated(r=-0.803, -0.862, P<0.001). The ROC analysis results showed that the cut-off values of D-D, NLR, BNP and the combined diagnosis of liver cirrhosis were 1.525, 5.740, 200.075 and 0.485 respectively, and the areas under the curve were 0.974, 0.993, 1.000 and 1.000 respectively. The combined diagnosis was higher than the single diagnosis.Conclusion The combined detection of D-D, NLR and BNP has high sensitivity and specificity in the diagnosis and treatment of AECOPD, and has high diagnostic value, which is worthy of clinical promotion.
Key wordsAcute exacerbation of chronic obstructive pulmonary disease    D-dimer    Neutrophil lymphocyte ratio;B-type natriuretic peptide    Diagnostic value
    
基金资助:江西省卫生健康委科技计划项目(202212381)
引用本文:   
肖士滨,张裕芳,黄昌艳. D-二聚体、NLR、BNP联合检测在慢性阻塞性肺疾病急性加重期诊治中的临床应用价值[J]. 中国当代医药, 2022, 29(24): 92-94-98.
XIAO Shibin,ZHANG Yufang,HUANG Changyan. Clinical application value of combined detection of D-dimer, NLR and BNP in the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary diseas. 中国当代医药, 2022, 29(24): 92-94-98.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I24/92
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载